The world's biggest drugmaker beat Wall Street's profit expectations but narrowly missed its sales forecast. It lowered its adjusted profit forecast for 2012 by 6 cents, to $2.14 to $2.24 per share. Analysts had predicted $2.26 per share. Including one-time items, it expects earnings per share of $1.23 to $1.38.
New York-based Pfizer said the change was due to its recent decision to sell its infant-nutirition business to Swiss food and drink giant Nestle SA for $11.85 billion. The steep drop in Lipitor revenue was factored into its previous forecasts.
The maker of Viagra said net income was $1.79 billion, or 24 cents per share, down from $2.22 billion, or 28 cents a share, a year earlier.
Excluding one-time items, Pfizer would have made $4.43 billion, or 58 cents per share. Analysts were expected 56 cents a share.
Revenue totalled $15.4 billion, down 7 per cent from $16.5 billion a year ago. Analysts were expecting $15.46 billion.
Sales in the U.S., where Pfizer's patent expired on Nov. 30 for Lipitor, the top-selling drug in history, fell to $5.95 billion, from $7.02 billion. International sales edged up 1 per cent, to $9.45 billion.
Lipitor sales fell 42 per cent, to $1.4 billion from $2.39 billion.
"I am pleased with out first-quarter 2012 financial performance, which was driven by growth in certain brands including Celebrex, Enbrel and Lyrica, growth in key geographies such as China" and cost-cutting, CEO Ian Read said in a statement.
Revenue from prescription medicines fell 8 per cent to $13.07 billion, as sales declined in the oncology, primary care and specialty care businesses.
Revenue from pain reliever Celebrex climbed 7 per cent to $634 million, Enbrel for immune system disorders rose 3 per cent to $899 million and Lyrica, for fibromyalgia and pain, jumped 16 per cent to $955 million.
Generic competition cut total revenue by $1.3 billion, Read noted.
Pfizer's sales in emerging markets, considered the industry's best prospect for growth as developed countries try to rein in their spending on medicine, rose 6 per cent to $2.3 billion.
The established products business, which sells medicines that have gone off patent but remain popular, jumped 18 per cent, to $2.8 billion. That was mainly because Lipitor revenue was shifted to that business, from the primary care business. Specialty care revenue likewise was affected by shifting two smaller sellers that got generic competition from that category to established products, Xalatan for glaucoma and anti-fungal medication Vfend.
The animal health business saw revenue rise 4 per cent to $1.03 billion, while revenue from consumer health products such as Centrum vitamins fell 1 per cent to $735 million. The soon-to-be sold infant nutrition business posted a 9 per cent jump in revenue, to $513 million.
Linda A. Johnson can be followed at http://twitter.com/LindaJ_onPharma